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Introduction
Positron Emission Tomography (PET) allows to image the biodistri-
bution and kinetics of radiopharmaceuticals in brain with great accuracy
and minimum invasiveness [1]. Interpreting these data by means of spe-
ci￿c mathematical models can improve the kind and quality of information
that can be extracted allowing the quanti￿cation of various physiological
parameters as, for example, the penetration of the blood-brain barrier by
the ligand; the volume of distribution of the tracer; the binding potential;
the receptor occupancy; the receptor a￿nity and density in a given region
[2]. This information can be used to monitor the progress of neurological
diseases or to assess the e￿ects of speci￿c drugs, such as their penetration
into target sites, their binding to speci￿c receptors and their e￿ects on the
metabolic processes [3].
Various models have been proposed in the past 30 years to convert
the radioactive tracer concentrations detected by a PET tomograph in an
organ or tissue (more precisely, in a region of interest [ROI] or in a unit
of image [pixel or voxel]) into measures of physiological parameters [4].
Although each of them starts from di￿erent assumptions, most of them
require the knowledge of the concentration of the radioligand inside both
the tissue and the arterial plasma. The ￿rst constitutes the output of the
model and it is obtained directly from the PET images while the second
represents its input (it is through the arterial blood that the tracer reaches
the tissues) and its measurement is more problematic.
The standard approach to obtain the Arterial Input Function (AIF)
consists in the cannulation of the radial artery of the patient, through
which blood samples are collected during the scan time. Undoubtedly,
this is an invasive technique and, although it is considered safe [5], it is2 Introduction
often cause of discomfort in the patient. Furthermore, the handling and
analysis of numerous blood samples require adequate facilities, special care
and technical expertise by the operator [6].
Given the issues related with arterial sampling, over the years new
methods have been developed to eliminate, or at least reduce, this practice.
One of the most promising approach consists in replacing the individual
arterial measurements with the average of the AIFs of a population of sub-
jects previously acquired. Before its application, the resulting curve has
to be calibrated through individual information (venous samples, covari-
ates,...) of the subject under analysis [7].
This method has been validated almost exclusively with [ 18F]-FDG
[7] [8] and only a few works have been reported using other tracers [9].
One of the aims of this study is to identify an optimal protocol for the
application of this technique and, subsequently, to assess its performance
highlighting the advantages and risks associated with its use.
The second part of the study is focussed on another method, called
SIME (SIMultaneous Estimation). Proposed by Feng and colleagues in
[10], this technique consists in estimating the input function and the tissue
parameters of multiple ROIs simultaneously. This approach requires a
parametric description of the AIF and the model most commonly used for
this purpose was proposed again by Feng in [11]. In this thesis the ability
of Feng’s model to describe correctly the AIF of other tracers than [ 18F]-
FDG (for which it was designed) is assessed and new models are proposed
which could possibly constitute an improvement.Chapter 2
Data sets and quanti￿cation
methods
2.1 Data sets
In dynamic PET studies radioactive tracers are used to obtain kinetic
information of the system under analysis. These are chemical compounds
in which one or more atoms have been replaced by a radioisotope (all the
tracer considered in this study were marked with the 11C isotope). Accord-
ing to the physiological process under investigation, tracer may either be a
direct radiolabeled version of a naturally occurring compound, an analog
of a natural compound, or a unique compound, perhaps a radiolabeled
drug [3]. The tracers available for this study were:
L-[1-11C]leucine: Leucine is one of the 20 standard amino acids and it
has a relevant role in the constitution and maintenance of the muscular
tissue. It promotes the protein synthesis in muscles and liver, it slows
down the breakdown of muscle proteins and it is involved in the regen-
eration processes [12]. In PET studies, L-[1- 11C]leucine is marked with a
radioactive isotope in order to tracer its incorporation inside the proteins,
allowing thus the measurement of the protein synthesis [13].
[11C]DASB: 11C-3-Amino-4-(2-dimethylaminomethylphenylsulfanyl)ben-
zonitrile, abbreviated as [11C]DASB, is a compound that binds with high
a￿nity and selectivity to the serotonin (5-hydroxytryptamine, or 5-HT)
transporter [14]. This transporter is the primary target for selective sero-
tonin reuptake inhibitors (SSRIs), which in turn are an e￿ective treatment
for majordepressive disorder, obsessive compulsive disorder, posttraumatic4 Data sets and quanti￿cation methods
stress disorder, generalized anxiety disorder, and other mood and anxiety
disorders [15].
[11C]PiB: [11C]PiB stands for Pittsburgh Compound-B, an amyloid-bind-
ing radiotracer used in PET scans to image beta-amyloid plaques in neu-
ronal tissue. The measurement of amyloid deposition can be used to im-
prove Alzheimer’s disease diagnosis and antiamyloid therapy assessment
[16].
[11C](R)-rolipram: Rolipram is an inhibitor of Phosphodiesterase-4
(PDE4), an enzyme that metabolizes cAMP which in turn is thought
to play an important role in the mechanism of action of antidepressants
[17]. The radiolabeled active enantiomer of rolipram, [ 11C](R)-rolipram,
has been used with PET to image and to quantify PDE4 in brain [18].
The data sets were made available by the Section of Neuroadaption and
Protein Metabolism of the National Institute of Mental Health, NIH, USA
(L-[1-11C]leucine) [13]; the Department of Psychiatry, Columbia Univer-
sity College of Physicians and Surgeons, New York ([ 11C]DASB) [15] ; the
University of Pittsburgh Alzheimer’s Disease Research Center, Pittsburgh,
USA ([11C]PiB) [16] and by the Molecular Imaging Branch, National In-
stitute of Mental Health, Bethesda, USA ([ 11C](R)-rolipram) [18].
2.1.1 Arterial data
The measured AIFs as well as the whole blood time activity curves of
all subjects related to all the four data sets were available. All the blood
samples were manually collected through the radial artery of the patients
according to a sampling protocol which envisaged a higher frequency at
the beginning of the exam, when the tracer kinetic was faster, followed by
a gradually decreased frequency as the exam reached its end.
Tracer
Number of Number of Infusion Exam duration
subjects samples time (s) (min)
L-[1-11C]leucine 50 35-41 120 75-90
[11C]DASB 30 31 30 120
[11C]PiB 20 30 20 90-130
[11C](R)-rolipram 10 23 60 90
Table 2.1. Main characteristics of the arterial data sets2.2 Quanti￿cation methods 5
All data are expressed in KBq=ml except the [11C]DASB ones be-
cause they were normalized by the dose injected (they are expressed in
normalized-dose units). Furthermore, as regards the L-[1- 11C]leucine data-
set, also the 11CO2 (main result of the metabolism of the molecule) activity
in blood was available. Finally, all data were corrected for the radioactive
decay. In table 2.1 the principal characteristics of each dataset are sum-
marized.
2.1.2 PET images
PET images of three L-[1-11C]leucine and three [11C](R)-rolipram sub-
jects were available. All of them were acquired with high resolution to-
mographs, allowing to obtain a voxel size of 1:2  1:2  1:2mm3. The
full volumes were acquired in 42 times frames for L-[1- 11C]leucine subjects
and 33 for [11C](R)-rolipram. All images were corrected for attenuation,
scatter and radioactive decay.
Furthermore, magnetic resonance images were co-registrated to the
PET images in order to de￿ne the following ROIs in all subjects: cerebel-
lum, thalamus, putamen, caudate, hippocampus.
2.2 Quanti￿cation methods
2.2.1 Compartmental models
Compartmental models describe the system under analysis postulating
a structure for the non accessible portion consisting of distinct compart-
ments which are interconnected by pathways representing ￿uxes of mate-
rial and/or biochemical conversions [19]. The structure must have solid
grounds in biochemistry and physiology since this kind of models are used
to de￿ne the relationship between the measurable data and the physiolog-
ical parameters that a￿ect the uptake and metabolism of the tracer.
L-[1-11C]leucine
In ￿gure 2.1 it is shown the compartmental model that was implemented
in this study for describing the behaviour of L-[1- 11C]leucine in brain. It
is a heterogenous model composed by two homogeneous subregions and a
compartment associated to metabolites. However, this is a simpli￿cation
over the heterogenous model of L-[1- 11C]leucine presented in [20] since the6 Data sets and quanti￿cation methods
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Figure 2.1. Compartmental model of L-[1-11C]leucine: k1(a;b) and k2(a;b) are the
rate constants for transport of L-[1-11C]leucine from plasma to tissue and back,
respectively; k3(a;b) is the rate constant of the formation process of the metabolite
(catabolism, transamination and decarboxylation) and, ￿nally, k4(a;b) is the rate
constant of incorporation of L-[1-11C]leucine into proteins.
number of homogeneous subregions is not de￿ned. The choice made re￿ects
the results obtained in [21] where 86% of the ROIs analyzed could be
described by two homogeneous subregions (the remaining 14% necessitates
of three subregions).
The radiotracer concentration measured by the PET scan ( Cm) in-
cludes the contribution of both regions of free L-[1- 11C]leucine (Ce) and L-
[1-11C]leucine incorporated into proteins (P). Each of these homogeneous
regions contributes to the heterogeneous tissue for a volume fraction equal,
respectively, to wa and wb (wa  0, wb  0 and wa + wb = 1). The PET
measure includes also the activity in the blood Vb  Cb, where Vb is the
portion of the volume occupied by the blood and Cb the concentration of
radioligand in whole blood and the main product of the metabolism of
the radiotracer, 11CO2. Assuming that the metabolite ￿xing is negligible
over the exam time and that its di￿usion in brain rapidly equilibrates with
arterial blood, its concentration can be approximated by the term Vd  Cc,
where Cc is the metabolite concentration in whole blood, while Vd is the
blood distribution volume in brain, which was set equal to Vd = 0:41 [20].2.2 Quanti￿cation methods 7
The radiotracer concentration in the tissue is thus given by:
Ctiss(t) = wa[CEa(t) + Pa(t)] + wb[CEb(t) + Pb(t)] (2.1)
while the measurement equation is:
Cm(t) = (1   Vb)  [Ctiss(t) + Vd  Cc(t)] + Vb  Cb(t) (2.2)
Unfortunately the wa and wb parameters are not uniquely identi￿-
able, i.e. their value can not be determined from the data available. For
this reason it was renounced to give a separate description of the two com-
partments which describe the L-[1- 11C]leucine incorporation into proteins
in favour of a unique trapping compartment. In fact the model described
by equations 2.1 and 2.2 is equivalent to a ￿rst-order compartmental model
with a trapping component, 2 equilibrating components, one metabolite
compartment of known concentration, and one blood component, that is:
Ctiss(t) = 0
Z t
0
Cp(z)dz +1
Z t
0
Cp(z)e
 1(t z)dz +2
Z t
0
Cp(z)e
 2(t z)dz
(2.3)
where the model parameters have been reformulated in the following
way:
0 =
wak1ak4a
k2a + k3a + k4a
+
wbk1bk4b
k2b + k3b + k4b
1 =
wak1a(k2a + k3a)
k2a + k3a + k4a
2 =
wbk1b(k2b + k3b)
k2b + k3b + k4b
(2.4)
1 = k2a + k3a + k4a
2 = k2b + k3b + k4b
As main parameter of interest the trapping rate constant KI was
considered, which is equals to 0.
[11C](R)-rolipram
The [11C](R)-rolipram model is a 2-tissue compartment model and it is
depicted in ￿gure 2.2. As for L-[1- 11C]leucine, Cp represents the plasmatic
tracer concentration, i.e. the input of the system. CF+NS and CS are the
compartments relative to the free and non-speci￿cally bound tracer and
the speci￿cally bound tracer respectively [18].8 Data sets and quanti￿cation methods
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Figure 2.2. 2-tissue compartment model of [11C](R)-rolipram: k1 and k2 corre-
spond to the speed of in￿ow and out￿ow of radioligand through the blood brain
barrier; k3 and k4 correspond to the speed of transfer of the radioligand between
the compartment of free and non-speci￿cally bound tracer and the compartment
relative to the [11C](R)-rolipram bound with speci￿c receptors.
The equations of the system are:
(
_ CF+NS(t) = k1Cp(t) + k4CS(t)   (k2 + k3)  CF+NS(t)
_ CS(t) = k3CF+NS(t)   k4CS(t)
(2.5)
while the measurement equation is:
Cm(t) = (1   Vb)  [CF+NS(t) + CS(t)] + Vb  Cb(t) (2.6)
where Vb and Cb were already de￿ned with L-[1-11C]leucine.
As parameter of interest the total distribution volume Vt, which
equals the ratio at equilibrium of total radioactivity in brain to the to-
tal plasma concentration, was chosen. Vt is obtained as:
Vt =
k1
k2

1 +
k3
k4

(2.7)
2.2.2 Spectral Analysis
Spectral Analysis (SA) is a technique ￿rst introduced by Cunningham
and Jones in 1993 [22] for the analysis of dynamic PET data. The strength
of this method is that with relatively few assumptions it allows to identify
the tissue kinetic parameters without knowing the compartmental struc-
ture of the system. One of these assumptions is that the tracer system
is linear, time-invariant (LTI) and its eigenvalues and coe￿cients are all
real-valued and non-positive [23]. These conditions are generally met in2.2 Quanti￿cation methods 9
dynamic PET studies. For this kind of systems, the impulse response can
be written as:
h(t) =
M X
i=1
i  e
 it (2.8)
where i and  i are respectively the coe￿cients and the eigenvalues
of the system and M is unknown.
Since the system is LTI, its response, i.e. the tracer concentration in
the tissue, can be calculated through the convolution operator:
Ctissue(t) = Cp(t)  h(t)
=
M X
i=1
i 
Z t
0
Cp(z)  e
 i(z t)dz (2.9)
While the measurement equation is:
Cm(t) = (1   Vb)  Ctissue(t) + Vb  Cb(t) (2.10)
SA requires to de￿ne a grid of M ￿xed s that covers an appropri-
ate spectral range, where M has to be ￿high￿ (  100). Once the s are
￿xed, the problem of estimating the remaining parameters becomes linear
and it can be easily solved using a Weighted linear Non-Negative Least
Squares (WNNLS) estimator, where the weights to be used are the same
already de￿ned in subsection 2.2.1. The result of the estimation is called
￿spectrum￿: it is important to note that, even if there is a large number of
coe￿cients to be estimated, at most N (i.e. the number of time samples)
of them can be nonzero, so there are few positive peaks in the spectrum.
By convention the higher s are called ￿high-frequency￿ components
and they should be related to the vascular volume, while s close to 0 are
referred to as ￿low-frequency￿ components and they account for irreversible
trapping of the tracer. The components in between are called ￿intermediate
frequencies￿ and they re￿ect the tissue activity of the tracer (also referred
to as equilibrating components) [4].
To clarify, even if the technique is called spectral analysis and the s
are referred to as frequencies, SA does not operate in the frequency domain
but exclusively in the time domain.10 Data sets and quanti￿cation methods
When using SA, the two parameters of interest, KI for L-[1-11C]-
leucine and Vt for [11C](R)-rolipram, are given by the following formulas:
KI = 0 (2.11)
Vt =
M X
i=1
i
i
(2.12)
2.2.3 Spectral Analysis with Iterative Filtering
Noise in data greatly in￿uences the accuracy with which very low fre-
quency and high frequency components can be detected. For this reason a
re￿nement of the SA technique that incorporates a numerical ￿ltering step
was proposed in [21] and called Spectral Analysis with Iterative Filtering
(SAIF).
The basic idea of this method is that all the components with expo-
nents greater than zero but less than L are assumed to have been shifted
from 0 (see equation 2.9) due to noise in the data and components with
exponents greater than U are assumed to be connected to the blood vol-
ume term. L and U are called cut o￿ frequencies and need to be ￿xed a
priori.
A two steps numerical ￿lter was thus de￿ned: initially the equilibrat-
ing components are removed and new values of the trapping component
and Vb are estimated; then this two are removed from the data and the
equilibrating components are re-estimated. All the process is repeated un-
til reaching the stabilization of the WRSS (Weighted Residuals Sum of
Squaresp) yielding to better accuracy in the trapping component 0 and
Vb estimation.Chapter 3
Average-Based Input Function
Average-Based Input Function (ABIF) method is founded on the hy-
pothesis that di￿erent subjects who undergo the same PET study share
an identical shape, but di￿erent amplitude, of the Arterial Input Func-
tion (AIF). Under this assumption it is ideally possible to substitute the
individual AIF of the subject under analysis with the one of any other sub-
ject, after having properly scaled it. For this purpose only a single arterial
sample could be extracted from the patient, greatly reducing his discom-
fort during the exam and considerably simplifying the exam procedure for
clinicians. In practice, since data are a￿ected by measurement errors, it is
preferable to average the AIFs of many subjects and scale the result with
one or two arterial samples [9].
One condition that this approach requires to be satis￿ed is that the
PET exams have to be consistent between subjects: in particular, the
infusion protocol has a signi￿cant in￿uence on the AIF shape and it is
therefore advisable the use of a computer driven pump in order to eliminate
a source of uncertainty. The tracer dose is usually calculated on many
factors and it also depends on the patient anthropometric parameters and
so it may change from subject to subject. However, provided that it varies
within certain limits, the tracer dose should a￿ects the amplitude, but not
the shape, of the AIF, leaving the ABIF hypothesis satis￿ed. Actually in
this kind of studies it is often used the normalized AIF instead of the AIF
itself. This is calculated dividing the latter by the dose injected so as to
make it less variable between di￿erent subjects. However this passage is not
strictly necessary in the ABIF method since the scaling process overrides
the normalization (both scaling and normalizing consist in multiplying the
AIF for a constant term).12 Average-Based Input Function
Another aspect that must be taken into account is the population
composition: while it is quite reasonable to assume that a population of
healthy patients with comparable ages who undergo the same PET study
may share a similar shape of the AIF (the extent to which this assertion
is true is actually one of the key point of this chapter), this may not be
the case when the population is composed by a mixture of healthy and
unhealthy subjects or people with really di￿erent ages. Pathologies, in
particular cardiovascular diseases (high pressure, ...), or even the state
(awake, asleep or anesthetized) of the patient might potentially alter the
AIF shape. These are just speculations but before applying the ABIF
approach, it is important to asses if the same-shape hypothesis holds true
in the population under analysis.
Finally, the tracer itself may constitute a limit to the applicability of
this method: di￿erent tracers have di￿erent kinetics (here with kinetics it
is intended the variation of the tracer concentration inside plasma and not
the variation inside the tissue under analysis) and there are no guarantees
that if the same-shape hypothesis holds for one tracer it will do the same for
another. In particular literature lacks of information about the application
of the ABIF method in dynamic PET studies with other tracers than 2-
deoxy-2-(18F)￿uoro-D-glucose (FDG) [7] [8] and only a few works have
been reported using non-FDG brain tracers [9][24][25].
ABIF approach is emerging between the minimally invasive tech-
niques because of its relative ease of implementation: it does not require
any particular mathematical skill (unlike SIME approach) and it does not
present signi￿cant issues. Of course it requires a su￿ciently rich dataset
of subjects whose AIFs have been previously collected with the standard
method (arterial sampling).
In the ￿rst part of the study it was supposed that the populations under
analysis satisfy the same-shape hypothesis and the attention was focused
on determining the optimal settings of the ABIF approach. In fact, even if
it does not seem to present any particular di￿culty, this approach involves
a sequence of steps that leaves some kind of arbitrariness to the operator
dealing with them. One of the key factors is represented by the number
of subjects to be averaged in order to calculate a reliable ABIF. Of course
this depends mainly on the noise present in the data and on the variability
of the tracer between subjects (the more homogeneous this is, the fewer
subjects will be needed). However, if the number of subjects that must be3.1 Materials 13
used is too high, the ABIF methods will lose most of its attractiveness: in
fact it would be necessary to directly measure the AIF of tens of subjects
with the invasive method before being able to use the ABIF approach and
there are not many centers who can perform such a large study (it should
be remembered that this approach applies only to consistent exams and
the data collected from one study may not be used for another).
The calibration step (formerly called ￿scaling￿) is another critical
point. It consists on the calculation of a Correcting Factor (CF) that
has to be multiplied to the averaged AIFs in order to take account of
the amplitude variability between subjects. The CF is usually obtained
by the ratio between the population AIF value at a certain time and the
concentration of tracer in the subject at the same time acquired from an
arterial or venous sample [7]. As suggested in [9], not all the times at
which the sample is extracted are equally good. In order to improve the
robustness of the method, in this study at least two samples were always
used for the calibration step. This allowed some degrees of freedom on the
choice of the sampling times and even on the methods used for calculating
the CF. Both were examined in detail with the purpose of ￿nding the
optimal combination. At the end of this part the entire procedure for the
de￿nition of the ABIF was completely and optimally de￿ned.
The successive part of the study is focused on the evaluating the
reliability of the ABIF approach itself. Here the key point is whether or not
this method can e￿ectively be used to replace the measured AIF. This was
tested by comparing the tissues kinetic parameter estimates using as input
￿rst the ABIF and then the measured AIF (i.e. Gold standard). Tissue
quanti￿cation was performed by means of spectral analysis and spectral
analysis with iterative ￿ltering (see section 3.5), both applied voxel-wise.
3.1 Materials
The ￿rst part of the study was conducted on all the four data sets
described in section 2.1 (L-[1-11C]leucine, [11C]DASB, [11C]PiB, [11C](R)-
rolipram), while the second part, i.e. the evaluation of the impact of using
ABIF on the tissue parameters estimations, was performed only on the
L-[1-11C]leucine and [11C](R)-rolipram ones.
About the L-[1-11C]leucine dataset, three subjects were excluded
from the study because the rising part of their AIFs was considerably14 Average-Based Input Function
shorter than normal. Probably di￿erent infusion protocol or dose injected
were responsible of these e￿ects. The L-[1- 11C]leucine dataset was there-
fore reduced to 47 subjects.
As regards the [11C]PiB dataset, two subjects were eliminated due to
their abnormal AIF shapes which indicates that probably something went
wrong during theirp acquisition or the preprocessing step. The dataset
considered was therefore composed by only 18 subjects.
For what concerns the [11C](R)-rolipram and the [11C]DASB data
sets, they were used in their entirety.
3.1.1 Dataset variability
In order to understand the degree to which each dataset approximates
the same-shape hypothesis, a few parameters were individuated in each
AIF and the range within they vary was evaluated. These parameters are:
￿ t0 (min): it represents the instant in which the AIF starts to rise,
i.e. when the tracer arrives at the place of measurement;
￿ tp (min): Time to Peak, it denotes the time in which the tracer
concentration reaches its maximum;
￿ yp (KBq=ml for all the subjects except [11C]DASB where it is ex-
pressed as dose-normalized unit): it indicates the tracer concentra-
tion at the time tp;
￿ tail (see yp): it’s the average of the tracer concentrations measured
in the last three samples;
The parameters distributions within each dataset are shown in ￿gure
3.0. yp is by far the most variable parameter but this is not a problem since
it is related with the amplitude, and not the shape, of the AIFs. The range
within t0 and tp is quite narrow: the largest di￿erence can be found in the
L-[1-11C]leucine dataset where tp shows a minimum-maximum di￿erence
of around 1 min (￿gure 3.0ap). Unlike yp, these parameters are related
to the AIF shape and, more precisely, they indicate that the curves are
translated on the temporal axis respect to each other.3.1 Materials 15
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Figure 3.0. AIFs parameters distribution within each data sets
3.2 ABIF construction
In this section the mathematical passages needed to obtain the ABIF
are discussed. For the sake of simplicity, the procedure is explained with
reference to a single generic dataset. The results are valid for all the data
sets considered in this study.
The ￿rst step carried out to build an ABIF was the averaging of the
individual AIFs available. Since the sampling grid changed from subject
to subject and given the temporal misalignment of the AIFs mentioned in
the 3.1.1 subsection, this step required a few preliminary substeps:
1. the average time to peak ( ^ tp) was calculated and all the AIFs were
translated so as to make the individual tp coincide with ^ tp;
2. a virtual grid Tv was created. The starting time was taken at tinit =
0, the distance between two consecutive points was calculated as
step = ^ tp=20 (so that ^ tp 2 Tv ) and the ￿nal time was set at tend =
min

t : t  max

tendi   tpi + ^ tp
	
^ t  0 (mod step)
	
, where i in-
dicates the i-th AIF used. Tv was therefore an equally spaced grid
which contained ^ tp and whose ￿nal point was greater than the ￿nal
point of all the aligned AIFs used;
3. the averaged AIF was thus calculated as ^ Cp(t) = 1
N
PN
i=1 lin[Cpi(t 
tpi+ ^ tp)], where lin[] represents the linear interpolation operator and3.2 ABIF construction 17
N is the number of AIFs used. When (t   tpi + ^ tp) was greater than
tendi, lin[] behaved as a linear extrapolation operator, while when
(t   tpi + ^ tp) was lower than zero, it returned zero.
3.2.1 Calibration
Once the average AIF was calculated, the next step was to scale it to
the proper amplitude. This phase takes the name of ￿calibration￿ and it
requires one or more blood samples. If only one blood sample ( Cpi(t1)) is
available this passage is quite simple and the ABIF of the i th subject is
given by:
ABIFi(t) = CF  ^ Cp(t) where CF =
Cpi(t1)
^ Cp(t1)
(3.1)
However, in this study at least two samples were always used to scale
^ Cp(t). Three di￿erent calibration techniques were tested in order to deter-
mine the best one:
Calibration 1: mean-based method
The ￿rst technique is an extension of the 3.1 equation when M blood
samples are available. It simply consists on calculating the mean CF and
for this reason it is called mean method.
ABIFi(t) = CF  ^ Cp(t) where CF =
1
M
M X
j=1
Cpi(tj)
^ Cp(tj)
(3.2)
Calibration 2: linear least squares method
The second technique is called least squares method and it consists in
￿nding the CF that minimize the sum of the squared di￿erences between
the blood samples and the ABIF. This can be expressed as:
ABIFi(t) = CF  ^ Cp(t) where
CF = argmin
CF
(
M X
j=1
[CF  ^ Cp(tj)   Cpi(tj)]
2
)
(3.3)
CF can be expressed in closed form as:18 Average-Based Input Function
CF =
PM
j=1 ^ Cp(tj)  Cpi(tj)
PM
j=1 ^ Cp(tj)2 (3.4)
Calibration 3: non-linear least squares method
The third and ￿nal technique is an attempt to correct not only the
amplitude but also the position of the tp of the ABIF. This is achieved
￿nding both a CF and a time shift ts that minimize the sum of the squared
di￿erences between the blood samples and the ABIF. That is:
ABIFi(t) = CF  ^ Cp(t   ts) where
[CF;ts] = argmin
CF;ts
(
M X
j=1
[CF  ^ Cp(tj   ts)   Cpi(tj)]
2
)
(3.5)
Unfortunately there is no closed form for the equation 3.5 because the
problem is non-linear in the parameters (and it is therefore called non-
linear least squares method). In its implementation a constrain was set on
ts in order to make the tp of the ABIF ranging between the minimum and
maximum tp of the AIFs used.
3.2.2 Sampling time
The samples used for the calibration step are crucial for the correct
estimation of the ABIF [9]. For this reason three di￿erent con￿gurations
were tried.
Initially three blood samples, taken at the times t1 = 10min, t2 =
50min and t3 = 80min, were used for the calibration process. All these
samples were chosen after the peak of the curve with the aim of covering
the largest portion of the AIF after the tp.
Then, the number of samples used was reduced to two and only the
samples at the times t1 = 10min and t2 = 50min were kept. This was
done in order to evaluate how the performance changed when less samples
were employed.3.3 Assessment of ABIF performance 19
Finally, an attempt to calibrate the averaged AIF using the tail, i.e.
the last three samples, was made. The reason for this choice was that after
a certain period of time the tracer concentration in the venous vessels tends
to match the one in the arterial vessels. If the use of these proves to be
e￿ective, the arterial samples may be easily replaced by the venous ones,
greatly simplifying the exam procedure.
3.2.3 Number of subjects
The last factor analyzed which could have an impact on the performance
was the number of AIFs averaged together to obtain the ABIF. Intuitively,
the more AIFs are averaged, the better the performance. The aim is to ￿nd
a compromise between the number of subjects required and the ability to
correctly reconstruct the curve. Starting from a minimum of ￿ve subjects,
the ABIF performance were evaluated increasing this number up to using
the entire dataset minus the subject under analysis.
3.3 Assessment of ABIF performance
3.3.1 Performance indices
In order to asses how each of these three factors ap￿ects the performance
of the ABIF method, it was necessary to evaluate all the possible combi-
nations. Before doing so, it was essential to de￿ne how the performance
was quanti￿ed. This was done using the following performance indices:
￿ MSE: Mean Squared Error, calculated between the estimated ABIF
and the measured AIF of the subject under analysis. Given Cpi(t)
de￿ned for t 2 Ti, where Ti = ft1i;t2i;:::;tji;:::;tMig and ABIFi(t)
de￿ned for t 2 Tv, the MSE between ABIFi(t) and Cpi(t) is calcu-
lated as:
MSEi =
1
Mi
X
t2Ti
flin[ABIFi(t)]   Cpi(t)g
2 (3.6)
where lin[] represents the linear interpolation operator de￿ned in
section 3.2.
￿ AUC: Delta Area Under the Curves, intended as the relative per-
centage di￿erence between the AUCABIFi and AUCi. That is:
AUCi = 100 
AUCABIFi   AUCi
AUCi
(3.7)20 Average-Based Input Function
Unlike the MSE index, the AUC is insensitive to errors of oppo-
site sign: if the ABIF underestimates the AUC of the ￿rst part of
the curve and overestimates the second part, the resulting AUC
will not re￿ect the error. In order to address, at least in part, this
issue, the index was split in two: AUCpeak and AUCtail, the ￿rst
considering the area from t = 0 to t = 10min, while the second
considering the remaining part. In order to avoid encumbering the
reading, hereinafter only the AUC will be mentioned, but every
time this is done, all the three indices will be meant. For this study,
all the AUCs were computed using the trapezoidal method.
3.3.2 Leave-one-out approach
A leave-one-out scheme was used to assess how the three factors - cali-
bration method, sampling times and number of subjects - a￿ects the two
performance indices - MSE and AUC. Fpor each subject all the factors
were made to vary one by one, generating the corresponding ABIF by using
the rest of the dataset and calculating the two performance indices at each
variation. More in detail, the adopted scheme consisted of the following
steps:
1. the i-th subject was extracted from the dataset and it was considered
as the subject under analysis. This means that this subject’s AIF
was supposed to be unknown and thus it had to be estimated through
the ABIF method;
2. 1000 di￿erent subsets composed by j randomly chosen AIFs were
generated from the rest of the dataset. Each subject could be part
of more than one subsets but two di￿erent subsets must di￿er for at
least one subject (see ￿gure 3.1);
3. the AIFs of each of these subsets were averaged together in the way
discussed at the beginning of the section 3.2. This passage led to
obtain 1000 di￿erent averaged AIF.
4. each of this averaged AIFs was then calibrated with all the possible
combination of the three calibration methods with the three sampling
times. This means that for each averaged AIF, nine di￿erent ABIFs
were generated (see table 3.1);
5. MSE and AUC were computed between each of the 9000 ABIFs
and the measured AIF of the subject under analysis.3.3 Assessment of ABIF performance 21
Subject under analysis
Subsets composed by 
j diﬀerent subjects 
(1000 subsets overall)
Full dataset
Figure 3.1. Exempli￿cation of the subsets generated from the dataset for each
subject under analysis.
6. for each of the nine combinations of the calibration settings, 1000
values of both the performance indices were thus available. These
represented the ABIF capacity of approximating the measured AIF
of the ith subject given a particular ￿xed setting: a ￿xed calibration
method applied with samples taken at ￿xed times and using a curve
obtained by averaging j subjects. What changed in the computation
of these 1000 indices were just the subjects composing the subset
used for creating the ABIF. The discussion on how the choice of the
subjects a￿ected the method performance are deferred to the second
part of this study (section 3.5). For this part the 1000 values were
considered as repeated measurements of the same quantity and thus
only their averages were kept: ^ MSE and  ^ AUC
7. the whole process was repeated for all the subjects composing the
dataset (N subjects). This led to N estimates of ^ MSE and  ^ AUC,
one for each subject. The mean and the standard deviation of these
quantities were computed so as to have only one value (and its stan-22 Average-Based Input Function
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s Mean Mean Mean
t=10,50,80 t=10,50 t=tail
Least squares Least squares Least squares
t=10,50,80 t=10,50 t=tail
Non-linear Non-linear Non-linear
t=10,50,80 t=10,50 t=tail
Table 3.1. Combining the calibration methods proposed in subsection 3.2.1 with
the sampling times discussed in subsections 3.2.2 gives nine alternative ways to
perform calibration.
dard deviation) for each of the two indices for a given calibration
setting (intended both as the method and as the sampling times)
using a generic population of j subject to calculate the ABIF. In
other words, the two values Mean ^ MSE and Mean ^ AUC and their
respective standard deviations indicate how good the ABIF approx-
imates the measured AIF on average and how this performance may
change from subject to subject.
3.4 Results
The four ￿gures 3.2 - 3.5 allow to have a straightforward vision of how
all the variables involved in the ABIF method impact on the performance
indices and they lend themselves to an easy comparison of all the possible
settings considered in this study.
3.4.1 Sampling times for calibration
Comparing the three columns, which represents the sampling times used
for calibration, it emerges that calibrating using the last three samples al-
ways performs worse than the other possibilities. In fact, observing the
Mean ^ MSE and the Mean ^ AUCpeak indices in the right columns, it can
be seen that their values are always the highest. For some particular
settings the Mean ^ AUCtail values are actually smaller than when other
sampling times are employed. The reason is soon explained: the sampling3.4 Results 23
schedule employed for the measured AIF is such as to have less and less
frequent samples as the exam reaches its end. Since the Mean ^ AUCtail
considers only the ￿nal portion of the AIF, its value is calculated on rel-
atively few samples, three of which are actually known. Since these three
samples are the last three, they are also the most spaced and thus the
corresponding area they cover is high when considering only the ￿nal por-
tion of the AIF. This implies that when used in the calibration method,
independently on which of the three techniques is implemented, they pro-
vides a lot of information to correctly estimate the ￿nal portion of the
AIF, strongly staggering the Mean ^ AUCtail value. Its main contribution
is in fact given by known information and the index no more indicates
the ability of the ABIF method to estimate the unknown part of the AIF.
Thus, since this index is not reliable and given the results of the other
two indices, it can be concluded that late samples, even if attractive (they
easily could have been substituted with venous samples), may not be the
best choice for the calibration step.
Comparing the ￿rst two columns of the ￿gures emerges that all the
indices are practically identical with a slightly lower indices in the central
column (t1;2 = 10;50min). It was just seen that the calibration using the
last three samples always performed poorly, so probably even in this case
the use of the sample at the time t = 80min should be avoided.
3.4.2 Calibration method
As concern the calibration methods, the non-linear least squares one
can be immediately excluded from the comparison: looking at the L-[1-
11C]leucine (3.2) and the [11C]PiB (3.4) ￿gures, it can be noted that the
Mean ^ MSE index (￿rst row) with the non-linear method (green) is by far
the highest. Moreover, it increases as more subjects are used.
This behaviour can be explained recalling how the method works: in
addition to a constant CF, the algorithm tries to recover the peak position
estimating the delay ts between the ABIF and the measured AIF (see the
speci￿c paragraph in subsection 3.2.1). Since the method is indeed non-
linear, a constraint was set on ts in order to make the tp of the ABIF
ranging between the minimum and maximum tp of the AIFs used. As the
number of AIFs used increases, the constraint becomes less and less rigid
allowing more freedom to the ts parameter and since this method clearly
fails to recover the correct peak position, the results tend to be more and24 Average-Based Input Function
more unreliable.
The [11C](R)-rolipram dataset is too poor to make this kind of rea-
soning, but still it can be see that the Mean ^ MSE index get higher instead
of decreasing.
Why this does not happen with [11C]DASB is soon explained: looking
at the ￿gure 3.0 about the data sets variability it can be noted how most
of the [11C]DASB subjects (19/30) share an identical tp. This implies that
the constrain on ts remains rigid even if the number of subjects increases.
The other two indices, Mean ^ AUCpeak and Mean ^ AUCtail, are
not a￿ected by the time shift as the area under the curve remains un-
changed but since the aim of this part is to determine the optimal way of
recovering the AIF, it is of secondary importance that the area of the esti-
mated AIF is quite correct if the curve pro￿le is completely wrong. Thus,
given its not reliable performance, this method was de￿nitely rejected.
Comparing the other two calibration techniques, the following pattern
emerges: the linear least squares method (red) is almost always associated
with better Mean ^ MSE and Mean ^ AUCtail values while the mean-based
method (blue) generates better Mean ^ AUCtail values.
The two techniques are based on two di￿erent concepts: the mean-
based method minimizes the relative di￿erence between the ABIF and the
measured samples; the linear least squares method minimizes the absolute
di￿erence instead. In fact, looking at the equation 3.2 relative to the mean-
based method, it can be noted that the ratios, and not the di￿erences,
between the two curves are considered. The linear last squares method,
instead, considers the square of the di￿erences, an absolute value.
Now, since all the sampling times considered are after the tp, they
lay in the decreasing part of the curve. With the mean method the higher
samples ￿count￿ the same as the lower because they are divided by the
curve ^ Cp(t) which theoretically has the same shape but a di￿erent ampli-
tude of the measured AIF. However, if the curves are subtracted as in the
least squares method, the higher samples will ￿count￿ the most because at
those times the curves are more distant and the algorithm tries to minimize
the (square of the) distance.3.4 Results 25
Considering the performance indices, the Mean ^ MSE indicates the
absolute di￿erence between the estimated and the measured curves, thus
the least squares method performs better; the Mean ^ AUCpeak measures
the relative di￿erence of the ￿rst part of the curve, precisely the part that
is favorite by the last squares algorithm, so again the least squares method
performs better; the Mean ^ AUCtail, instead, is related to the remaining
part of the area under the curves which is reconstructed worse by this
method and so its values are greater.
Since Mean ^ AUCpeak is usually grater than Mean ^ AUCtail (i.e.
the ￿rst part of the curve is reconstructed worse than the second with both
method) and taken into account the Mean ^ MSE values, the linear least
squares method was chosen as the optimal method.26 Average-Based Input Function
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Figure 3.2. L-[1-11C]leucine: this ￿gure shows how the three perfor-
mance indices, Mean ^ MSE (￿rst row), Mean ^ AUCpeak (second row) and
Mean ^ AUCtail (third row), vary when the calibration is performed using
the samples at the times t1;2;3 = 10;50;80min (￿rst column), at the times
t1;2 = 10;50min (second column) and at the last three times (third column).
For each panel, blue line represents the mean-based calibration method, red line
represents linear last squares method and green line the non linear least-squares
method. Each line represents the behaviour of the index as function of the
number of subjects used for de￿ning the ABIF3.4 Results 27
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Figure 3.3. [11C]DASB: see description in ￿gure 3.2.28 Average-Based Input Function
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Figure 3.4. [11C]PiB: see description in ￿gure 3.2.3.4 Results 29
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Figure 3.5. [11C](R)-rolipram: see description in ￿gure 3.2.30 Average-Based Input Function
3.4.3 Number of subjects
Calibration performed with the linear least squares method, applied us-
ing the samples at the times t1;2 = 10;50min was identi￿ed as optimal.
In this subsection all the results were obtained using that con￿guration
and the attention was focused on the impact that the number of subjects
averaged together have on the AIF reconstruction. Again, the aim is to
identify the optimal number.
L-[1-11C]leucine
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Figure 3.6. L-[1-11C]leucine: Mean ^ MSE with its standard deviation (left) and
Mean ^ AUC with its standard deviation (right) plotted versus the number of
subjects. The linear least squares method applied using the samples taken at
the times t1;2 = 10;50min is used for the calibration step.
From the ￿gure 3.6 it can be seen that both indices get lower when
the number of subjects averaged increases. This is quite evident for the
Mean ^ MSE, that falls by around 16:3% when all the dataset (minus the
subject under analysis), instead of only 5 subjects, is used. The improve-
ment of the Mean ^ AUC index is less appreciable: the index value varies
between 5:70% (5 subjects used) and 5:38% (all the dataset used). The
standard deviations of both indices seem not to bene￿t from the raised
number of subjects used: for the Mean ^ MSE the improvement is less
than 1% (0:89%), while the standard deviation of the Mean ^ AUC index
actually gets worse, passing from 3:0% to 3:4%.3.4 Results 31
Assuming the Mean ^ MSE index reached a plateau at the end of the
graph, a threshold of 5% was chosen to determine the optimal number of
subjects to be used. In other words, the optimal number was identi￿ed
as the lower number whose corresponding Mean ^ MSE value is at most
5% grater than the minimum Mean ^ MSE. This number is 15 and the
corresponding value is 4:86% grater than the minimum.
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Figure 3.7. [11C]DASB: see description in ￿gure 3.6.
Similarly to L-[1-11C]leucine, also with [11C]DASB both indices decrease
as the number of subjects used increases (￿gure 3.7). Again the Mean ^ MSE
index experiences a more marked reduction (13:7%) than the Mean ^ AUC
does (1:01%) while the standard deviation remains almost constant: it
slightly decreases (3:9%) in the Mean ^ MSE graph and it widens from
8:9% to 9:6% in the Mean ^ AUC graph.
As regards [11C]DASB, the optimal number of subjects to be used
identi￿ed with the 5% threshold is 13. The corresponding Mean ^ MSE
value is 4:7% grater than the minimum.
[11C]PiB
Even with [11C]PiB the pattern remains the same (￿gure 3.8): the dif-
ference between the Mean ^ MSE value when using only 5 subjects and32 Average-Based Input Function
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Figure 3.8. [11C]PiB: see description in ￿gure 3.6.
the value when using all the dataset is about 13:2%, while the same dif-
ference, but with regard to the Mean ^ AUC index, is just about 0:55%.
Again, the Mean ^ MSE standard deviation decreases ( 2:2%) while the
Mean ^ AUC standard deviation rises from 8:7% to 9:2%.
For this tracer, the resulting optimal number of subjects is 10 (whose
corresponding Mean ^ MSE is 4:83% greater than the one obtained using
the entire dataset). However, in this case, since the number of subjects
available were not very high (18), the assumption that the Mean ^ MSE
index reached a plateau at the end of the graph is not properly veri￿ed.
Hence, the optimal number may be higher (and a richer dataset should be
used to determine its correct value).
[11C](R)-rolipram
As regards the [11C](R)-rolipram dataset, only 10 subjects were available
but the considerations made for the other tracers are still valid. Both the
indices decrease as the number of subjects used increases. These improve-
ments are of the order of 8% for the Mean ^ MSE index and 0:4% for the
Mean ^ AUC index. The standard deviations of these indices narrow in
the case of the former index (2:3%) and expand in the second case (from
5:9% to 6:5%).
Similarly to what happened with the [ 11C]PiB one, the [11C](R)-
rolipram dataset available was too poor to allow the identi￿cation of the
optimal number of subjects to be used in the ABIF method.3.5 Impact on quanti￿cation 33
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Figure 3.9. [11C](R)-rolipram: see description in ￿gure 3.6.
3.5 Impact on quanti￿cation
As result of the ￿rst part of this study, an optimal procedure for the
application of the ABIF method was individuated and fully de￿ned. The
best calibration technique identi￿ed was the least squares method while
for the optimal sampling times, t1 = 10min and t2 = 50min were chosen
among the possibilities tested. Finally, the number of AIFs to be used
depended on the speci￿c tracer.
The aim of this second part was to asses if this method could be
applied with success in replacement of the full arterial sampling and with
what degree of con￿dence the results on the tissue parameters estimations
could be accepted. Another key point was to understand what relevance
the subjects used have, i.e. if two ABIFs generated with the same set-
tings but with di￿erent subjects give similar results or not. In order to do
so, the tissue parameters estimation was performed on the L-[1- 11C]leucine
and the [11C](R)-rolipram data sets. For the L-[1- 11C]leucine dataset, three
subjects whose PET images were available were chosen and the trapping
rate constant KI was estimated using SAIF, applied voxelwise. This anal-
ysis was performed several times using as input functions ABIFs generated
from di￿erent subsets of 15 (i.e. the optimal number identi￿ed in the ￿rst
part) subjects each. Finally, SAIF was applied on the three subjects us-
ing their measured AIF. The KIs so obtained were considered as the gold
standard against which to compare the ones obtained with the ABIFs. As
regard the [11C](R)-rolipram dataset, the parameter of interest is the distri-
bution volume Vt. Since this tracer had reversible kinetics, SAIF could not34 Average-Based Input Function
be used and thus standard SA, still applied voxelwise, was used instead.
Even for this dataset, the analysis were performed on three subjects using
several di￿erent ABIFs and the measured AIF.
3.5.1 Implementation
As concern the implementation of the SAIF and SA methods, the soft-
ware SAKE [26] was used. As s grids, and for the SAIF also the cut-
o￿ frequencies, the default values were kept: about the grid the num-
ber of components were set to 100, starting from Min = 0:01min 1 to
Max = 1min 1; with SAIF, the passband ￿lter had the two cuto￿ fre-
quencies at L = 0:1min 1 and U = 0:5min 1.
As regards the error law that describes the measurement error of the
L-[1-11C]leucine PET data, this was assumed to be [27]:
SD(ti) /
s
zi  ekti
ti
(3.8)
where zi is the measured datum at the time ti; k is the decay constant
of the 11C isotope and it is equal to k = 0:034min 1 and ti is the time
interval of the PET scan during the acquisition of the ith datum.
The error law used with [11C](R)-rolipram was assumed to be [18]:
SD(ti) /
r
zi
ti
(3.9)
All the input functions used (measured and estimated with ABIF) were
assumed to be error free.
3.5.2 Results
In this section a comparison between measured AIF and two ABIFs
generated using di￿erent subsets of subjects was made. This provided
an idea of the performance variability of the method depending on the
population of subjects used for ABIF de￿nition.3.5 Impact on quanti￿cation 35
L-[1-11C]leucine
From the L-[1-11C]leucine dataset the subject 6 was selected since it
exhibited the widest di￿erence between the best and the worst case. In
￿gure 3.10 the two ABIF used are shown: ABIF 1 gave the best results
while ABIF 2 the worst ones.
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Figure 3.10. Two ABIFs generated with the optimal settings using di￿erent
subsets of subjects (15 each). The blue circles represent the measured AIF.
The KI maps of the 100th slice generated with these two ABIFs and
with the measured AIF are shown in ￿gure 3.11. Visually the three maps
look almost identical, so the percentage error maps were computed as well
(right column). The percentage error e was de￿ned as:
e(x;y) = 100 
KI(x;y)   ~ KI(x;y)
KI(x;y)
(3.10)
where KI(x;y) represents the value of KI at the coordinates (x;y)
calculated with the measured AIF (Gold Standard) and ~ KI(x;y) represents
the same value but calculated with the ABIF.
The histograms of e computed with both ABIF for the slice 100 are
shown in ￿gure 3.12. The mean and the standard deviation of the error
committed using ABIF 1 (best case) are  2:01  2:23%, while they are
 8:02  2:48% when ABIF 2 (worst case) is used.36 Average-Based Input Function
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Figure 3.11. KI maps of one representative slice generated using as input
function the measured AIF (a), the ABIF 1 (b) and the ABIF 2 (d). Maps of
the percentage errors are shown as well (c)(e).3.5 Impact on quanti￿cation 37
Always in ￿gure 3.12, the scatter plots are shown as well. The regression
line for the best case has a slope of m = 0:988 and a y-intercept of q = 0:003
(in case of perfect match the previous values would have been m = 1 and
q = 0). The Pearson’s coe￿cient R2 is instead equal to 0:998 (1 in case
of perfect matching). As concern the worst case, m = 1:0423, q = 0:0004
and R2 = 0:997.
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(d) Scatter plot ABIF 2 - Worst case
Figure 3.12. Histograms of the errors (a, c) and scatter plots (b, d) of the
KI parameter of the same slice shown in ￿gure 3.11 when using the two ABIFs
compared to the gold standard38 Average-Based Input Function
[11C](R)-rolipram
As regards the [11C](R)-rolipram dataset, the subject who gave the most
di￿erent results when two di￿erent ABIF were used was the number 18.
In ￿gure 3.13 the measured AIF, the best ABIF (green) and the worst
(red) are shown. Since the optimal number of subjects to be used was not
de￿ned for this tracer, it was decided to ￿x this number as 5, corresponding
to half of the dataset available.
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Figure 3.13. Two ABIFs generated with the optimal settings using di￿erent
subsets of subjects (5 each). The blue circles represent the measured AIF.
In ￿gure 3.14, the three Vt maps, one for each input functions, of the
19th slice are shown as well as the corresponding error maps (see equation
3.10). The mean error and its standard deviation are  3:892:40% in the
best case and  48:09  11:63% in the worst.
As regards the scatter plots shown in ￿gure 3.15, for the best case (green)
m = 1:034, q = 0:004 and R2 = 0:99, while for the worst (red) m = 1:44,
q = 0:023 and R2 = 0:92.3.5 Impact on quanti￿cation 39
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Figure 3.14. Vt maps of one representative slice generated using as input func-
tion the measured AIF (a), the ABIF 1 (b) and the ABIF 2 (d). Maps of the
percentage errors are shown as well(c)(e).40 Average-Based Input Function
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Figure 3.15. Histograms of the errors (a, c) and scatter plots (b, d) of the Vt
parameter of the same slice shown in ￿gure 3.14 when using the two ABIFs.
3.5.3 Discussion
According to the tracer considered, this second part yielded to consid-
erably di￿erent results, almost of opposite sign: with L-[1- 11C]leucine the
maximum mean percentage error of the KI parameter encountered was
just around  8% and even in the worst case the correlation coe￿cient R2
kept over 0:99; with [11C](R)-rolipram the mean percentage error of the Vt
parameter reached and overcame the value of  48%, that is de￿nitely too
high to be accepted. What is really stunning is that the performance of
the method are highly dependant on the subjects used to de￿ne the ABIF.3.6 Conclusion 41
How to determine if the subjects used are suitable or not is actually a
big issue. In fact, it is not properly correct to speak about ￿good￿ subjects
in absolute terms: their goodness is relative to the subject under analysis,
they are good if their average shares the same shape of the one of the AIF
to be estimated. Since in practice the only information known about this
AIF are just two samples, the problem seems impractical.
One factor that could have in￿uenced the results obtained with the
[11C](R)-rolipram dataset is the low number of subjects used for the ABIF
de￿nition (5 subjects). In fact with L-[1- 11C]leucine, where 15 subjects
were used, the performance were much better. Increasing the size of the
subset used would likely mitigate the presence of outliers but this does not
solve the problem when the outlier is the subject under analysis himself.
Another di￿erence occurred between the two analysis performed is
the tissue parameter chosen: as regards the L-[1- 11C]leucine one, the pa-
rameter chosen was KI; as concern the [11C](R)-rolipram analysis, the
distribution volume Vt was selected. KI is a direct parameter, this means
that its value is calculated directly from the SAIF (it is the trapping rate
constant, it correspond to 0). On the other side, Vt is a derived parame-
ter, calculated from all the s and s obtained from the SA (see equation
2.7). The errors associated which each of these values propagates resulting
in an higher uncertainty of the Vt value. Unfortunately, the use of derived
parameters is necessary for clinical application, even with L-[1- 11C]leucine.
However, although all these problems just stressed are not trivial, the
real issue with the ABIF method is another: the results can not be trusted.
The error committed can be around 4% as well as around 50% without
any known possibility to discern between the two cases. No clue if the
parameters are over or underestimated. Even with L-[1- 11C]leucine there
are no guarantees that the error committed could not overcome the 8%
threshold and be much higher and this eventuality would be completely
invisible to the operator. In substance the method lacks a way of assessing
the accuracy of estimations.
3.6 Conclusion
ABIF approach is a relative simple technique that can be used when the
full arterial samples are not available. Despite its ease of implementation,
the method leaves some kind of arbitrariness to the operator and thus the42 Average-Based Input Function
￿rst step carried out was to de￿ne an optimal procedure. This was done
checking all the possible variables that might a￿ect the results, that are the
calibration method, the times of the samples used for the calibration step
and the number of subjects used for the ABIF de￿nition. The goal was to
determine the optimal combination of these factors. This means ￿nding a
trade-o￿ between the performance reached with a particular con￿guration
and the amount of data necessary to that particular combination (number
of subjects, number of samples used, computation time, ...).
The optimal procedure was identi￿ed pas the one which involves the
use of the samples at the times t1;2 = 10;50min in combination with the
least squares calibration method. The number of subjects to be used was
dependant on the tracer considered.
Nevertheless, even when all the optimal conditions are met, the perfor-
mance of this method strongly depends on the subjects used for the ABIF
construction and the subject under analysis itself. This was particularly
evident with the [11C](R)-rolipram dataset as the mean error committed in
the Vt estimation raised from around 4% to more than 48% just changing
the subjects averaged together.
With the L-[1-11C]leucine dataset performance was better and the
results seemed more robust. However, the big unsolved issue that a￿ect
the ABIF method is that there is no way to assess the goodness of the
results: the tissue parameters estimations can be completely wrong but
still looking as perfectly plausible.
In conclusion, the use of this approach should be limited to those arterial
data sets with homogeneous kinetics when the full arterial sampling is
impractical due to the patient condition and should be avoided when the
purpose of the study involve statistical comparisons between di￿erent data
sets.Chapter 4
Arterial Input Function
Modelling
In dynamic PET studies it may happen that a mathematical description
of the AIF is required. For example when the samples are collected by an
automatic machine, the data are too noisy to be used directly and they
need to be ￿tted with an appropriate model. A model is also useful for
estimating the measurement error associated with the samples and it can
also be applied in simulation studies.
In this chapter one of the most commonly used models, Feng’s model,
was analyzed in detail and particular attention was paid on evaluating the
best error law for describing the measurement error. The results shows that
Feng’s model is a￿ected by some issues. For this reason, three new models
were proposed and compared in order to overcome Feng’s limitations.
4.1 State of the art: Feng’s model
The model proposed by Feng in [11] is the solution of a LTI system
composed by two simple and one repeated eigenvalues. Its expression is
given by:
y(t) =
(
0 t  t0
[A(t   t0)   B   C]e (t t0) + B  e (t t0) + C  e 
(t t0) t > t0
(4.1)
where  and 
 are the simple eigenvalues while  is the repeated one,
i.e. the  exponential has two coe￿cients: A(t   t0) and  (B + C). The
reason of the presence of the repeated eigenvalue is, according to Feng, due44 Arterial Input Function Modelling
to the cardiac output and blood ￿ows. In fact the tracer arrives at and
leaves from the measurement site transported in these ways. Both phases
(arrival and leaving) are ￿fast￿ if compared to normal di￿usion processes
and thus the two eigenvalues associated should be high and close to each
other. For this reason, they are assumed to be equal ( ) and greater than
 and 
.
As regards the t0 term, this is a delay constant included to take into
account the time between the tracer injection (in the venous system) and
its arrival in the measurement site (artery). Obviously the tracer concen-
tration before its arrival (t  t0) is equal to 0 and thus the coe￿cients of
the system are calculated so as to satisfy the initial conditions of tracer
absence (their sum is equal to 0 when t = t0). Furthermore, all parameters
are assumed to be real-valued and positive.
4.1.1 Error Law
Before estimating the parameters of Feng’s model, it was necessary to
decide how to handle the measurement errors. However literature lacks of
information about the error law to be associated with the arterial samples.
For this reason four di￿erent laws were proposed and tested in order to
determine the most correct. A few assumptions were common to all of
them: the error term is a random variable vi, additive, with zero mean
and uncorrelated. This means that each datum zi at sample time ti can
be expressed as:
zi = yi + vi (4.2)
where yi is the value of the Feng’s model at the time ti.
In order to give a complete characterization of the error term vi,
its variance needs to be de￿ned. The variance of the error that a￿ects
radioactive measurements is usually assumed to have a Poisson statistic
[28]. That is:
V ar(vi) / zi (4.3)
Since the data available were corrected for the radioactivity decay, it
was hypothesized that the error should re￿ect this correction too. For this
reason a new variance was proposed, that is:
V ar(vi) / zi  e
kti (4.4)4.1 State of the art: Feng’s model 45
where k = 0:034min 1 and it is the decay constant of the 11C isotope.
This second error law was called ￿exponential￿. Finally, other two error
laws were proposed:
V ar(vi) / 1 (4.5)
V ar(vi) / z
2
i (4.6)
called ￿constant SD￿ and ￿constant CV￿ error laws respectively. These two
were introduced as they are really common in physiological models.
These four error laws were used to determine the weights to be associ-
ated with each datum in a WNLS (Weighted Non-linear Least Squares)
estimator. More in detail, the relative weights assigned to each datum
correspond to the inverse of the variance of the error associated with that
datum. The term ￿relative￿ is used because the variance is supposed to be
known up to a proportionally constant 2, which is estimated a posteriori
as:

2 =
WRSS
N   M
(4.7)
where WRSS is the Weighted Residual Sum of Squares obtained with the
estimated parameters, N the number of data and M the number of param-
eters.
4.1.2 Initial parameters
Since Feng’s model is not linear in its parameters and due to the sensi-
tivity of the estimates to the initial values, the ￿tting process required to
de￿ne an approximate solution. An initial value for each parameter had
to be estimated, from where the algorithm could start its research of the
correct solution. The parameter t0 was ￿xed as the time of the sample
preceding the ￿rst sample whose value was more than 10% of the peak
value. As regards the other parameters, the initial values where obtained
implementing a modi￿ed version of the curve peeling method described in
[19].
The assumption of this method is that the ￿rst two exponentials ( 
and ) do not give a signi￿cant contribute to the ￿nal portion of the curve,
but this is determined almost exclusively by the last exponential. Thus,46 Arterial Input Function Modelling
the initial parameters C0 and 
0 can be estimated imposing the passage of
that exponential for the last two samples. That is:

0 =
log(zend 1)   log(zend)
tend   tend 1
(4.8)
C0 = zende

0(tend t0) (4.9)
Once the last exponential is estimated, it can be subtracted from the
data in order to obtain:
z
0
i = zi   C0e

0(ti t0) (4.10)
The previous step is repeated imposing the passage of the second
exponential for two consecutive samples taken around the 10th minute of
the modi￿ed data z0. That is:
0 =
log(z0
10m)   log(z0
10m+1)
t10m+1   t10m
(4.11)
B0 = z
0
10me
0(t10m t0) (4.12)
The last two parameters are obtained imposing the passage to the
peak (tp;zp). This results in really long calculus and the ￿nal formulation
was reached with the aid of the software Wolfram Mathematica 8 [29]:
0 =
1
tp0 (C0etp00 + etp0
0 (B0   etp00zp))


e
tp0
0  
B0   e
tp00zp + B0tp00

+ C0e
tp00(1 + tp0
0)+
 
C0e
tp00 + e
tp0
0  
B0   e
tp00zp

W(tmp)

(4.13)
A0 =
B0
 
0   etp0(0 0)0

+ C0
 
0   etp0(0 
0)
0

 1 + tp00
(4.14)
where
tp0 =tp   t0 (4.15)
tmp =  
(B0 + C0)
C0etp00 + etp0
0 (B0   etp00zp)

e
C0e
tp00( 1+tp00)+e
tp0
0(B0( 1+tp0
0) e
tp00zp( 1+tp0(0+
0)))
C0e
tp00+e
tp0
0(B0 e
tp00zp)
(4.16)
and where W() is the Lambert W function.4.1 State of the art: Feng’s model 47
4.1.3 Evaluation of error law
Parameters were estimated with a WNLS estimator and the weights
were determined by the four error laws saw in subsection 4.1.1. In order
to choose the best error law, the following factors were considered:
1. weighted residuals: they have to be uncorrelated, with zero mean
and variance equal to 1. Unfortunately there were too few samples
to implement any statistical test, so the correlation was assess by
visually inspecting the weighted residuals plot;
2. Residual Sum of Squares: RSS gives an indication of how good the
model ￿ts the data. The lower, the better.
Error law RSS
Weighted residuals
mean Var Correlation
L-[1-11C]leucine
Constant SD 5260 -0.0273 0.8616 High
Constant CV 7375 0.0427 0.1656 Low
Poisson 5708 0.0243 0.7708 Low
Exponential 5669 0.0253 0.7654 Medium
[11C]DASB
Constant SD 0.026 -0.0464 0.8238 High
Constant CV 0.057 0.0585 0.1430 Low
Poisson 0.033 0.0359 0.7656 Low
Exponential 0.032 0.0334 0.7615 Medium
[11C]PiB
Constant SD 1587 -0.0522 0.8139 High
Constant CV 3867 0.0600 0.1382 Low
Poisson 2090 0.0269 0.7317 Low
Exponential 2091 0.0270 0.7299 Medium
[11C](R)-rolipram
Constant SD 7291 -0.0354 0.7582 High
Constant CV 11599 0.0625 0.2621 Low
Poisson 8340 0.0297 0.6956 Low
Exponential 8288 0.0307 0.6922 Medium
Table 4.1. Impact of the di￿erent error laws on the Feng’s model ￿t performance
From the table 4.1 emerges that the Poisson and constant CV er-
ror laws gives the less correlated residuals. Between the two, Poisson is
associated with lower RSS, weighted residuals averages closer to zero and
weighted residuals variances closer to one. For these reasons, Poisson error
law was selected as the best for all data sets.48 Arterial Input Function Modelling
4.1.4 Feng’s model limitations
Even if with the Poisson error law Feng’s model gave the best results, its
overall performances were poor. As can be seen in ￿gure 4.1, the model is
not able to describe correctly the curve. The peak is clearly underestimated
and the weighted residuals are still correlated. This behaviour is common
to all the four tracers considered.
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Figure 4.1. Example of Feng’s model ￿t with a L-[1-11C]leucine plasmatic con-
centration curve (above) and weighted residuals (below).
It has been speculated that this behavior may be due to the inability
of the model to describe correctly the rising and the decreasing part at the
same time. To verify this, it was tried to ￿t only the wash-out phase of
the curve with Feng’s model. Then, the resulting weighted residuals were
aligned in order to make the tp of the curve equal to zero. Subsequently,
the residuals corresponding to the same times were averaged together (us-
ing nearest interpolation when the times did not coincide perfectly). The
resulting curve is shown in ￿gure 4.2.
If Feng’s model were adequate to describe the wash-out phase, the
residuals would have been random and their average would have been close
to zero. The curve in ￿gure 4.2 is referred to the L-[1- 11C]leucine dataset
and it shows a complete di￿erent result: the residuals are still correlated
and they follow an oscillating pattern. Similar results were found with the
other data sets.4.2 New Models 49
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Figure 4.2. The curve shows the average weighted residuals obtained ￿tting the
AIF curves after the peak with Feng’s model. The dataset used for this picture
is the L-[1-11C]leucine one.
4.2 New Models
Three hypothesis were made regarding the inability of Feng’s model to
correctly describe the data, each of which gave rise to a new model:
1. Feng’s model underestimates the peak because of limitations
in the algorithm In order to take into account this possibility, the
estimation was performed constraining two parameters so as to make the
model passing for the peak. This new model was called Feng Constrained
and it has the same formulation of Feng (equation 4.1) with the following
constrains:
A =
B
 
   etp( )

+ C
 
   etp( 
)


 1 + tp
(4.17)
B =
etp( 
)  
 Cetp
 + etp(+
)zp( 1 + tp) + Cetp(1 + tp(  + 
))

etp + etp( 1 + tp(   ))
(4.18)
2. Considering the infusion time to be negligible is a wrong as-
sumption. This possibility was tested modeling the infusion as a trans-50 Arterial Input Function Modelling
lated rect function of duration equal to T and applying it as input of the
Feng’s model. Since it is derived from a LTI system, the output is given
by the convolution operator and thus this new model was called Feng*rect.
Only for this model, the parameter t0 was not ￿xed before the estimating
step. The model expression for t > t0 is:
y(t) =
Z t
t0
([A(   t0)   B   C]e
 a( t0) + Be
 b( t0) + Ce
 c( t0))
[1(t   )   1(t      T)]d
(4.19)
3. The oscillations are due to the presence of a complex eigen-
value in the system. Complex eigenvalues in physiological systems are
known to exist [30] and they manifest with a dumped oscillating mode.
This can be modelled as a sin function modulated by an exponential func-
tion. The new model proposed consists of adding to the Feng’s model
this oscillating term. The new model was called FengComplex and its
expression for t > t0 is:
y(t) =[A(t   t0)   B   C   Dsin()]e
 (t t0) + Be
 (t t0)+
Ce
 
(t t0) + De
 (t t0) sin[!(t   t0) + ]
(4.20)
Given the high number of parameters of this model (10), the ￿tting
process was divided in three steps:
1. data were ￿tted with Feng’s model and the residual were obtained;
2. residuals were ￿tted with the dumped sin function: De (t t0) sin[!(t 
t0) + ];
3. the parameters just obtained were used as initial parameters for the
whole model.
All the parameters of all the three new models were estimated assuming
the measurements error could be described by the Poisson error law.
4.2.1 New models evaluation
In the evaluation of these three models, Feng Constrained was almost
immediately discarded since its performance were even worse than the4.2 New Models 51
original Feng’s model. Figure 4.3 represents one of the best ￿t obtained
with this model and it clearly shows that it is not adequate to describe
correctly the data.
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Figure 4.3. Example of Feng Constrained model with a L-[1-11C]leucine plas-
matic concentration curve.
In order to choose the best model between the two remaining, the prin-
ciple of parsimony was followed. The aim was to ￿nd the model which is
best able to ￿t the data with the minimum number of parameters. The
Akaike information criterion (AIC) and the Schwarz criterion were used.
The model which had the smallest criterion was the best. This two criteria
are calculated in the following way:
AIC = N ln(WRSS) + 2P (4.21)
SC = N ln(WRSS) + P ln(N) (4.22)
where N represents the number of samples, P the number of parameters
of the model and WRSS is the Weighted Sum of Squared Residuals.
In table 4.2 the average of the two criteria are reported. Feng*rect always
has the lowest value (except for the SC criterion in [ 11C](R)-rolipram). For
this reason it was chosen as the best model.
An example of two ￿ts are shown in ￿gure 4.4. As it can be seen, the
Feng*rect model describes quite correctly the data even if the residuals are
not properly uncorrelated. Plotting together the residuals obtained ￿tting
the data with the Feng*rect model (￿gure 4.5) shows that the oscillating
pattern is still present. Even with FengComplex the residuals maintain
this behaviour.52 Arterial Input Function Modelling
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(a) Feng*rect
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(b) FengComplex
Figure 4.4. Example of Feng*rect and FengComplex models with a L-[1- 11C]-
leucine plasmatic concentration curve.
0 10 20 30 40 50 60 70 80 90 100
−4
−3
−2
−1
0
1
2
3
4
time (min)
 
 
Figure 4.5. The weighted residuals obtained ￿tting the L-[1-11C]leucine AIFs
with Feng*rect model exhibit an oscillating behaviour4.3 Conclusion 53
Model WRSS AIC SC
L-[1-11C]leucine
FengComplex 9.61 57.35 53.15
Feng*rect 8.67 49.65 46.71
[11C]DASB
FengComplex 3.60 37.24 32.15
Feng*rect 2.89 28.31 24.75
[11C]PiB
FengComplex 4.07 38.29 33.06
Feng*rect 5.19 35.46 31.80
[11C](R)-rolipram
FengComplex 4.21 34.37 27.98
Feng*rect 6.90 33.29 28.82
Table 4.2. WRSS, Akaike (AIC) and Schwarz (SC) indices of the FengComplex
and Feng*rect models
4.3 Conclusion
In this study Feng’s model was analyzed in detail. First, four possible
error laws were compared in order to determine the best possible error
law for the data sets considered, which resulted to be the Poisson error
law. Second, the critical step of determining the initial values for the
minimization algorithm was addressed implementing an automatic method
for their estimation from the data.
However, Feng’s model was designed to be used with [ 18F]FDG [11]
and when the tracer injection was a bolus. When used with other tracers
or when the infusion protocol was di￿erent, the model proved to be not
adequate to describe the data. For this reason new models were proposed.
Among all, the model called Feng*rect was chosen as the best. In fact
it was able to describe rather correctly both the rising and the wash-out
phase of the AIFs using the same number of parameters as Feng’s model.
Moreover, it estimated correctly the peaks and it did not require the t0
parameter to be ￿xed before the estimation phase.
As regards the residuals, even if improved, they still were corre-
lated. In particular they exhibit an oscillating behaviour whose cause is
not known.54 Arterial Input Function ModellingChapter 5
SIMultaneous Estimation
SIMultaneous Estimation (SIME) is a technique that consists in esti-
mating the tissue parameters of multiple Regions Of Interest (ROI) and
the input function parameters simultaneously. This approach was mainly
validated in simulation studies [10] [31] [32] or with [ 18F]FDG data [33],
while relatively little information can be found regarding other tracers [34].
In this ￿nal part of the study, the parametric model proposed in
chapter 4 to describe the input function (Feng*rect) was used in the im-
plementation of SIME method.
5.1 Methods
The compartmental models seen in subsection 2.2.1 describe the trans-
fer function of a generic region in brain for a given tracer. This generic
region can be seen as a LTI system, whose input is given by the plasmatic
concentration of tracer and whose output is measured by the PET scan.
If input and output functions are known, the estimation of the transfer
function parameters can be done applying non-linear regression analysis.
Nevertheless, it is not possible to obtain the input function and the system
transfer function simultaneously from the single output function. However,
from PET images multiple output functions of multiple ROI are available
and, even if each of them is described by a di￿erent transfer function, they
all share the same input function. It is therefore possible to estimate both
the input and the transfer functions taking advantage of the uniqueness of
the ￿rst.56 SIMultaneous Estimation
5.1.1 Mathematical formulation
As parametric expression of the input function, the Feng*rect model
proposed in chapter 4 was used. Its full expression is given by:
Cp(;T;t) =
8
> <
> :
0 t  t0 R t
t0([A(   t0)   B   C]e a( t0) + Be b( t0) + Ce c( t0))
[1(t   )   1(t      T)]d t > t0
(5.1)
where  = [A;B;C;;;
;t0]T and T is the infusion time, supposed to
be known.
The transfer function of a generic i th ROI is indicated as hi(Ki;t),
where Ki represents the vector of parameters associated with that ROI.
The output of the ith system, i.e. the tracer concentration Ctiin the ith
ROI, is thus given by:
Cti(;Ki;T;t) = hi(Ki;t)  Cp(;T;t) (5.2)
However, in the PET measures there is also a component related to
the blood volume as well as the eventual presence of metabolites. This can
be written as:
Cmi(;Ki;Vbi;Cother;T;t) = f[Cti(;Ki;T;t);Vbi;Cother] (5.3)
where Vbi is the percentage of the ith ROI volume occupied by blood,
Cother represents all the information about the tracer activity in whole
blood including metabolites and f[] is the function that combines all these
factors. In this study Cother was supposed to be known.
The objective function related to the tissue to be minimize is thus
given by:
(;K1;:::;KM;Vb1;:::;VbM) = (5.4)
M X
i=1
N X
j=1
wi(tj)[zi(tj)   Cmi(;Ki;Vbi;Cother;T;tj)]
2 (5.5)
where M is the number of ROI, N is the number of data available for
each ROI, zi(tj) is the PET measure of the ith ROI at the time tj and
wi(tj) is the weight to be associated with it, calculated as the inverse of
its variance.5.2 Materials 57
If nC arterial samples Pc are available the following term accounting
for the plasmatic modelp must be added:
nC X
c=1
vc[Pc   Cp(;T;tsc)]
2 (5.6)
where vc represents the weight to be associated with the arterial samples
(usually high) and tsc is the sampling time of the cth arterial sample.
5.1.2 Estimation
For each subject, ￿ve ROIs and the last three arterial samples were used.
As initial parameters of the input function the values obtained ￿tting all
the measured samples with the Feng*rect model were used. As regards the
initial parameters of the ROI transfer functions, the value obtained with
the Gold standard were used.
In order to further improve the parameter estimation, a bayesian
prior was assigned to the input function parameters. This prior was cal-
culated ￿tting the entire dataset (excluding the subject under analysis)
with the Feng*rect model and calculating, for each parameter, mean and
variance of the values estimated.
All the analysis were performed using the software SAAM II.
5.2 Materials
Initially this approach was thought to be applied to both the L-[1- 11C]-
leucine and [11C](R)-rolipram images dataset (see section 3.1). However,
the objective function obtained with L-[1- 11C]leucine data proved to be
particulary challenging to minimize and the algorithms used never con-
verged to an acceptable solution. For this reason, only the results obtained
with the [11C](R)-rolipram dataset are presented.
5.3 Results
An example of the results that can be obtained are shown in table 5.1.
As regards the transfer function, the average percentage error committed
in the ￿ve ROIs respect to the values obtained with the gold standard is58 SIMultaneous Estimation
below 20% for all parameters except Vb. Actually, Vb does not represent a
kinetic parameter as the others, but a volume and it is known to be more
problematic to estimate [34]. As concern the parameter of interest Vt, the
error committed is around 4% in all ROIs.
Input function Error Transfer function Average error SD error
parameters % parameters % %
A 13.28 k1 -20 1.7
B 20.60 k2 -4 2.0
C -6.97 k3 20 6.1
 -1.00 k4 -12 1.1
 6.31 Vb 37 5.5

 -1.68 Vt 4 0.8
t0 65.04
Table 5.1. Percentage errors between the parameters estimated with the SIME
method and the gold standard method of one [11C](R)-rolipram subject. As
regards the transfer function parameters, with average error is intended the
mean error between the ￿ve ROIs.
The input parameters do not have a physiological meaning, however
looking at ￿gure 5.1 it can be seen that the input function is estimated
quite well. Of course having chosen as initial parameters the value obtained
￿tting the Feng*rect model to all the measured samples and the use of a
bayesian prior have undoubtedly contributed to reach this good perfor-
mance. Nevertheless, the new model implemented in the SIME method
have proved to be adequate to describe the data.
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Figure 5.1. Input function as estimated with SIME of a [11C](R)-rolipram
subject compared to the measured input function.5.4 Conclusion 59
5.4 Conclusion
The aim of this chapter was not to reach an optimal implementation
of the SIME method and neither to evaluate its performance rigorously.
The aim was to obtain some preliminary results about the robustness and
￿exibility of the new proposed model for the description of the AIF, the
Feng*rect model.
Further studies are of course necessary to assess the model perfor-
mance when compared to other models and when it is applied in less ideal
condition. Moreover, the SIME method can be improved by implementing
more sophisticated algorithm to minimize the objective function (simu-
lated annealing was proposed in [31] and [34]); assigning optimal weights
to each ROI; using prior on the Vb parameter; ...
Nevertheless, despite all the limitations of this study, the Feng*rect
model proved to have a great potential and to give reliable estimation of
the AIF when used with SIME.60 SIMultaneous EstimationChapter 6
Conclusion
Dynamic PET quanti￿cation often involves the cannulation of the radial
artery of the patient, a practice considered invasive and cause of discomfort
for the patient. Furthermore, the handling and analysis of numerous blood
samples require adequate facilities, special care and technical expertise by
the operator. For these reasons in this study two alternatives to the arterial
sampling, called ABIF and SIME respectively, were analyzed.
As regards the ￿rst, two goals were pursued: determining an optimal
protocol evaluating the main factors that could a￿ect ABIF performance
and validating this approach with other tracers than [ 18F]FDG. It has been
found that despite the use of an adequate number of subjects, this method
is not able to completely recover the intra-subjects variability. Moreover
the ABIF de￿nition is heavily conditioned by the characteristics of the
individuals composing the population. With this method, the performance
are therefore unpredictable.
For all these reasons, the use of this approach should be limited to
those arterial data sets with homogeneous kinetics when the full arterial
sampling is impractical due to the patient condition and should be avoided
when the purpose of the study involve statistical comparisons between
di￿erent data sets.
As concern SIME, the study focused on the parametric description of
the arterial input function. The most commonly employed model found
in literature, Feng’s model, was originally designed for [ 18F]FDG and when
tested with the tracers considered in this study, it performed poorly. Among
the new models proposed, the modi￿cation of Feng’s model (taking into62 Conclusion
account the tracer injection time) proved to be adequate to describe cor-
rectly both the rising and the wash-out phase of the AIFs. This new model
does not introduce new parameters to the Feng’s original model, thus its
complexity was maintained unaltered.
Preliminary studies on the implementation of this new solution to
the SIME method shown that it has a great potential and it can achieve
reliable description of the AIF.Bibliography
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